CBD Changed Brain Waves and Improved Cognition in Boys With Severe Autism
In a double-blind crossover trial, 8 weeks of pharmaceutical CBD (Epidiolex) altered brain wave patterns and improved visual-motor and non-verbal cognitive abilities in boys with autism requiring higher support—and blood CBD metabolite levels predicted the brain changes.
Quick Facts
What This Study Found
This study analyzed EEG data from 24 boys with autism spectrum disorder (ASD) and higher support needs, drawn from a Phase II clinical trial of pharmaceutical-grade CBD (Epidiolex, up to 20 mg/kg/day).
The EEG analysis went beyond traditional approaches, examining both periodic (oscillatory) and aperiodic components of brain activity. After 8 weeks of CBD treatment, specific aperiodic EEG measures changed in ways that correlated with CBD metabolite levels in blood—providing a direct biological link between drug exposure and brain function.
The most striking finding: CBD metabolite levels were associated with improvements in visuomotor abilities and non-verbal cognitive skills. These are core deficit areas for children with ASD requiring higher levels of support, and there are few effective treatments for them.
The brain wave changes included a larger aperiodic offset across the scalp and a decreased aperiodic exponent—technical measures that reflect the overall excitation-inhibition balance of the brain. Given RTHC-00217's finding that cannabinoids affect the GABA excitation-inhibition balance, this EEG finding may reflect CBD modulating the same fundamental neural property in a therapeutic direction for ASD.
This is the first study to use FDA-approved purified CBD in children with ASD and higher support needs, and the first to link CBD blood levels directly to EEG biomarkers and cognitive outcomes in this population.
Key Numbers
N = 24 boys, ages 7–14. Higher support needs ASD. 8 weeks CBD (Epidiolex, up to 20 mg/kg/day). Double-blind crossover. Aperiodic EEG changes correlated with CBD metabolite levels. Improvements in visuomotor and non-verbal cognitive abilities.
How They Did This
Analysis of EEG data from 24 boys with ASD and higher support needs (ages 7–14) from a double-blind, placebo-controlled, crossover Phase II trial (NCT04517799). 8 weeks of daily CBD (up to 20 mg/kg/day Epidiolex). EEG at baseline, post-CBD, post-placebo, and post-washout. Linear mixed-effects models linking aperiodic EEG measures with CBD metabolite blood levels and cognitive outcomes.
Why This Research Matters
Children with ASD requiring higher levels of support have very few treatment options for core cognitive deficits. Current medications primarily address behavioral symptoms (irritability, aggression) rather than cognitive abilities. If CBD can improve visuomotor and non-verbal cognition—and this improvement is measurable via EEG biomarkers—it could represent a genuinely new therapeutic approach for the most affected children.
The Bigger Picture
This represents an entirely new therapeutic direction for CBD—beyond epilepsy (RTHC-00189, 00186, 00165) and pain (RTHC-00225) into neurodevelopmental conditions. The EEG biomarker approach connects to the broader effort to develop objective measures of cannabis/CBD effects (see RTHC-00221's UPE biomarker for anxiety). And the use of FDA-approved Epidiolex rather than unregulated CBD products means the results are clinically actionable.
What This Study Doesn't Tell Us
Small sample (24 boys). Only boys—ASD presents differently in girls and CBD effects may differ. The cognitive improvements were associated with CBD metabolite levels, not with treatment condition per se, suggesting individual pharmacokinetic variability matters. Crossover design means each child received both CBD and placebo, but period effects are possible. 8 weeks may not be long enough to assess sustained cognitive changes. Higher-support-needs ASD is heterogeneous.
Questions This Raises
- ?Would the cognitive benefits persist with longer treatment?
- ?Do girls with ASD show the same response?
- ?Could EEG biomarkers predict which children will respond to CBD before starting treatment?
- ?What is the optimal CBD dose for ASD—is 20 mg/kg/day the ceiling?
Trust & Context
- Key Stat:
- Evidence Grade:
- Double-blind, placebo-controlled, crossover Phase II trial with EEG biomarkers and blood-level correlations—rigorous design, though small sample.
- Study Age:
- Published in 2026 in Translational Psychiatry, representing a new frontier for CBD therapeutics.
- Original Title:
- Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support.
- Published In:
- Translational psychiatry, 16(1) (2026) — Translational Psychiatry is a reputable journal focusing on the intersection of psychiatry and neuroscience.
- Database ID:
- RTHC-08155
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- why-does-weed-make-you-emotional-thc
- thc-and-productivity-help-or-hurt
- thc-and-studying-cannabis-learning-research
Cite This Study
https://rethinkthc.com/research/RTHC-08155APA
Cazares, Christian; Hutton, Austin; Paez, Gisselle; Trauner, Doris; Voytek, Bradley. (2026). Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support.. Translational psychiatry, 16(1). https://doi.org/10.1038/s41398-026-03815-y
MLA
Cazares, Christian, et al. "Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support.." Translational psychiatry, 2026. https://doi.org/10.1038/s41398-026-03815-y
RethinkTHC
RethinkTHC Research Database. "Cannabidiol blood metabolite levels after cannabidiol treatm..." RTHC-08155. Retrieved from https://rethinkthc.com/research/cazares-2026-cannabidiol-blood-metabolite-levels
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.